CROHN'S DISEASE

This study observes 335 people with moderate to severe Crohn's disease who are taking Entyvio (vedolizumab) as part of their regular care. The goal is to see how safe and effective the drug is over the long term. Participants must have already tried other treatments without succe…

This study was designed to see if stem cells from a donor could safely treat fistulas (abnormal tunnels) in people with Crohn's disease who have a surgically created internal pouch. The trial was withdrawn before enrolling any participants, so no results are available. It would h…

This study aimed to test whether stem cells from bone marrow could safely help people with a severe form of pouchitis, a complication after colon surgery for inflammatory bowel disease. The trial was withdrawn before enrolling any participants, so no results are available. The ap…

This study tests whether a daily pill called upadacitinib can help adults with Crohn's disease stay in remission and avoid flare-ups over the long term. About 747 people who already responded to the drug in earlier studies will either continue taking it or switch to a placebo. Th…

This early-phase study tested an oral herbal formula (E-B-FAHF-2) in 7 adults with mild-to-moderate Crohn's disease. The goal was to see if it is safe and tolerable, and to gather early signs of whether it might help control the disease. The formula is a concentrated version of a…

This study tests an injectable drug called risankizumab for people with moderate to severe Crohn's disease, a condition that causes painful gut inflammation. About 276 adults will receive either the drug or a placebo for up to 24 weeks, followed by an open-label extension. The go…

This study tests whether a fecal transplant (FMT) can safely treat children with recurrent C. difficile infection, especially those with inflammatory bowel disease (IBD). Researchers will give FMT to 250 kids aged 3-21 and watch for side effects and whether the infection comes ba…

This study tests whether two special diets—a liquid formula diet or the specific carbohydrate diet—can help control active Crohn's disease or ulcerative colitis. About 40 adults with active disease will follow one of these diets for 6 weeks, then return to normal eating. Research…

This study looks at how well and how safely the drug mirikizumab works over the long term for people with Crohn's disease. About 1,000 adults who completed earlier mirikizumab studies will continue treatment for up to 52 weeks. The goal is to see if the drug can keep the gut heal…

This study tests a drug called guselkumab in 120 adults with Crohn's disease. The goal is to see if it can heal all layers of the digestive tract, measured by MRI scans at 48 weeks. Participants receive the drug and are monitored for healing and symptom changes.

This study tests a drug called guselkumab in about 1,400 people with moderate to severe Crohn's disease. The goal is to see if it can reduce symptoms and heal the gut lining better than a placebo or another active drug. Participants receive injections and are monitored for up to …

This study tests whether combining two drugs (guselkumab and golimumab) works better than either drug alone for people with moderate to severe Crohn's disease. About 703 adults will receive the combo or a placebo to see if it can bring about remission and heal the gut lining by w…

This early-stage trial aimed to test the safety of injecting donor stem cells around fistulas in people with Crohn's disease. The study planned to enroll 20 adults with complex or multiple fistulas, but was withdrawn before any participants were treated. The goal was to see if th…

This study follows 15,000 adults and children (age 2+) with Crohn's disease, ulcerative colitis, or indeterminate colitis for up to 5 years. Researchers will collect data on how patients respond to treatments, side effects, and disease changes in everyday medical practice. The go…

This study is not testing a new treatment. Instead, it looks back at the medical records of over 1,000 adults in Brazil with ulcerative colitis or Crohn's disease who are taking or have taken vedolizumab. The goal is to see how long people stay on the drug and what other treatmen…

This study looks at how well a tool called CDPATH™ can predict the risk of serious complications in people with Crohn's disease within the next 3 years. About 200 adults with Crohn's will use the tool to learn their risk level (low, medium, or high) and discuss treatment options …

This study is a long-term registry that follows nearly 5,000 children with inflammatory bowel disease (Crohn's, ulcerative colitis, or indeterminate colitis) to monitor their safety and health over time. Researchers collect information on side effects from treatments like inflixi…